Gene therapies offer tremendous promise—yet their high upfront cost has been a challenge for payers. Kellie Rademacher, Precision for Value’s VP, Access Experience Team, outlined the pros and cons in a talk at the Association of Managed Care Pharmacy Annual Meeting; Managed Healthcare Executive reports on it.

Read the article